As of 2026-09-14, the EV/EBITDA ratio of Jounce Therapeutics Inc (JNCE) is 1.06. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. JNCE's latest enterprise value is -51.62 mil USD. JNCE's TTM EBITDA according to its financial statements is -48.70 mil USD. Dividing these 2 quantities gives us the above JNCE EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 10.0x - 15.9x | 13.0x |
| Forward P/E multiples | 12.2x - 17.5x | 16.6x |
| Fair Price | (8.46) - (11.87) | (10.83) |
| Upside | -550.2% - -731.3% | -676.2% |
| Date | EV/EBITDA |